HRP20211749T1 - Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom - Google Patents
Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom Download PDFInfo
- Publication number
- HRP20211749T1 HRP20211749T1 HRP20211749TT HRP20211749T HRP20211749T1 HR P20211749 T1 HRP20211749 T1 HR P20211749T1 HR P20211749T T HRP20211749T T HR P20211749TT HR P20211749 T HRP20211749 T HR P20211749T HR P20211749 T1 HRP20211749 T1 HR P20211749T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- pyridines
- pyrrolo
- pyrimidine
- viral infections
- Prior art date
Links
- 206010022005 Influenza viral infections Diseases 0.000 title 1
- 150000005603 pentanoic acids Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 229960003971 influenza vaccine Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (7)
1. Spoj odabran od
[image]
[image]
2. Farmaceutski pripravak, naznačen time što sadrži spoj prema patentnom zahtjevu 1 zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili nosača.
3. Spoj prema patentnom zahtjevu 1 ili farmaceutski pripravak prema patentnom zahtjevu 2 naznačen time što je za upotrebu kao lijek.
4. Spoj prema patentnom zahtjevu 1 ili farmaceutski pripravak prema patentnom zahtjevu 2 naznačen time što je za uporabu u liječenju gripe.
5. Spoj prema patentnom zahtjevu 1 naznačen time što je za upotrebu u inhibiciji replikacije virusa gripe u biološkom uzorku ili pacijentu.
6. Spoj za uporabu u skladu s patentnim zahtjevom 5 naznačen time što nadalje uključuje zajedničko davanje dodatnog terapeutskog sredstva.
7. Spoj za uporabu prema patentnom zahtjevu 6, naznačen time što je dodatno terapeutsko sredstvo odabrano od antivirusnog sredstva ili cjepiva protiv gripe, ili oboje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150457 | 2016-01-07 | ||
| PCT/EP2017/050175 WO2017118680A1 (en) | 2016-01-07 | 2017-01-05 | Functionalized pentanoic acids for use in influenza viral infections |
| EP17700614.5A EP3400225B1 (en) | 2016-01-07 | 2017-01-05 | Pentanoic acids substituted by pyrrolo-[2-3,b]pyrimidine-pyridines for the treatment of influenza viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211749T1 true HRP20211749T1 (hr) | 2022-02-18 |
Family
ID=55070906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211749TT HRP20211749T1 (hr) | 2016-01-07 | 2017-01-05 | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10526338B2 (hr) |
| EP (1) | EP3400225B1 (hr) |
| JP (1) | JP7001601B2 (hr) |
| KR (1) | KR20180099839A (hr) |
| CN (1) | CN108473493B (hr) |
| AU (1) | AU2017205261B2 (hr) |
| CA (1) | CA3007758A1 (hr) |
| DK (1) | DK3400225T3 (hr) |
| EA (1) | EA201891576A1 (hr) |
| ES (1) | ES2902403T3 (hr) |
| HR (1) | HRP20211749T1 (hr) |
| HU (1) | HUE056457T2 (hr) |
| LT (1) | LT3400225T (hr) |
| MA (1) | MA43583A (hr) |
| SI (1) | SI3400225T1 (hr) |
| WO (1) | WO2017118680A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI639596B (zh) | 2009-06-17 | 2018-11-01 | 維泰克斯製藥公司 | 流感病毒複製之抑制劑 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| CN107759571B (zh) | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| US10647693B2 (en) | 2016-08-30 | 2020-05-12 | North & South Brother Pharmacy Investment Company Limited | Inhibitors of influenza virus replication, application methods and uses thereof |
| US10987354B2 (en) | 2016-12-15 | 2021-04-27 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US11098042B2 (en) | 2017-01-05 | 2021-08-24 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US10927118B2 (en) | 2017-03-02 | 2021-02-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI639596B (zh) * | 2009-06-17 | 2018-11-01 | 維泰克斯製藥公司 | 流感病毒複製之抑制劑 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2013184985A1 (en) * | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| BR112015011036B1 (pt) * | 2012-11-16 | 2022-02-01 | Janssen Sciences Ireland Uc | Derivados de 2-amino-quinazolina substituídos heterocíclicos, composição farmacêutica |
| BR112017002370B1 (pt) | 2014-08-08 | 2022-11-22 | Janssen Sciences Ireland Uc | Compostos indóis, composição farmacêutica que os compreende e seu uso na inibição da replicação do vírus da gripe |
| AU2015314394A1 (en) * | 2014-09-08 | 2017-03-02 | Janssen Sciences Ireland Uc | Pyrrolopyrimidines for use in influenza virus infection |
| MA42422A (fr) * | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
-
2017
- 2017-01-05 DK DK17700614.5T patent/DK3400225T3/da active
- 2017-01-05 EA EA201891576A patent/EA201891576A1/ru unknown
- 2017-01-05 EP EP17700614.5A patent/EP3400225B1/en active Active
- 2017-01-05 JP JP2018535337A patent/JP7001601B2/ja active Active
- 2017-01-05 LT LTEPPCT/EP2017/050175T patent/LT3400225T/lt unknown
- 2017-01-05 HR HRP20211749TT patent/HRP20211749T1/hr unknown
- 2017-01-05 KR KR1020187022012A patent/KR20180099839A/ko not_active Application Discontinuation
- 2017-01-05 ES ES17700614T patent/ES2902403T3/es active Active
- 2017-01-05 CN CN201780006031.XA patent/CN108473493B/zh not_active Expired - Fee Related
- 2017-01-05 WO PCT/EP2017/050175 patent/WO2017118680A1/en active Application Filing
- 2017-01-05 CA CA3007758A patent/CA3007758A1/en active Pending
- 2017-01-05 HU HUE17700614A patent/HUE056457T2/hu unknown
- 2017-01-05 SI SI201730989T patent/SI3400225T1/sl unknown
- 2017-01-05 US US16/068,315 patent/US10526338B2/en not_active Expired - Fee Related
- 2017-01-05 MA MA043583A patent/MA43583A/fr unknown
- 2017-01-05 AU AU2017205261A patent/AU2017205261B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US10526338B2 (en) | 2020-01-07 |
| SI3400225T1 (sl) | 2022-01-31 |
| DK3400225T3 (da) | 2022-01-03 |
| JP2019505518A (ja) | 2019-02-28 |
| KR20180099839A (ko) | 2018-09-05 |
| US20190023713A1 (en) | 2019-01-24 |
| EP3400225A1 (en) | 2018-11-14 |
| MA43583A (fr) | 2021-05-19 |
| ES2902403T3 (es) | 2022-03-28 |
| AU2017205261A1 (en) | 2018-06-28 |
| CA3007758A1 (en) | 2017-07-13 |
| JP7001601B2 (ja) | 2022-01-19 |
| HUE056457T2 (hu) | 2022-02-28 |
| LT3400225T (lt) | 2021-12-10 |
| CN108473493B (zh) | 2022-05-27 |
| EA201891576A1 (ru) | 2018-11-30 |
| EP3400225B1 (en) | 2021-11-10 |
| AU2017205261B2 (en) | 2021-03-25 |
| CN108473493A (zh) | 2018-08-31 |
| WO2017118680A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| HRP20230274T1 (hr) | Kemijski spojevi | |
| HRP20171512T1 (hr) | Derivati betulina | |
| HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| WO2017191258A9 (en) | Influenza mrna vaccines | |
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| JP2016508134A5 (hr) | ||
| EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| EA201991174A1 (ru) | Комбинация двух противовирусных препаратов для лечения гепатита c | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| SI2709613T1 (en) | Procedures for the treatment of HCV | |
| CU20170109A7 (es) | Derivado de quinoleina para tratar y prevenir infecciones virales | |
| ES2510940R1 (es) | Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas | |
| HRP20201645T1 (hr) | Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent | |
| MX2014004814A (es) | Compuestos y metodos para mejorar las respuestas inmunes innatas. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus |